Position in ENLV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$209,936
New position
Shares Held
225,738
first reported quarter
Ownership
1.34%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026PRELUDE CAPITAL MANAGEMENT, LLC holds $75,046,663 across 96 Biotechnology names. ENLV ranks #51 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
|
98,849 | $11,349,842 | |
| 2 | FOLD |
AMICUS THERAPEUTICS, INC.
|
639,885 | $9,252,737 | |
| 3 | PGEN |
Precigen, Inc.
|
1,270,053 | $4,915,105 | |
| 4 | APLS |
Apellis Pharmaceuticals, Inc.
|
111,468 | $4,484,357 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
111,593 | $3,091,126 | |
| 6 | PRAX |
Praxis Precision Medicines, Inc.
|
9,064 | $2,920,330 | |
| 7 | TERN |
Terns Pharmaceuticals, Inc.
|
54,825 | $2,890,374 | |
| 8 | COGT |
Cogent Biosciences, Inc.
|
64,222 | $2,471,904 |
All Filings in ENLV
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $209,936 | 225,738 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||